Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed by Lilu Anderson 25.06.2024 Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
ResMed, Inspire Medical Drop After Lilly’s Zepbound Study by Mark Eisenberg 24.06.2024 "ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Zealand Pharma Surges on Promising Weight Loss Drug Trial Results by Mark Eisenberg 21.06.2024 Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertain by Lilu Anderson 20.06.2024 Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Esperion Stock Downgraded Amid Merck’s Competitive Pressure by Mark Eisenberg 20.06.2024 Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Akero Therapeutics MASH Treatment Trial Data: Stock Up 21% by Mark Eisenberg 04.03.2024 The stock has dropped 29% in the last year, hitting a low of $11.25 on Oct. 27. A study shows ...
Otsuka’s Alzheimer Drug AVP-786 Fails Trial Phase by Lilu Anderson 13.02.2024 Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...